PR Newswire BiotechOriginal article
Skyhawk Therapeutics annonce les résultats finaux à quinze mois de l'essai clinique de phase 1/2 du SKY-0515 chez des patients atteints de la maladie de Huntington
Phase 1positiveSKY-0515Positive
AI Analysis
Summary
Skyhawk Therapeutics announced final 15-month data from its Phase 1/2 trial of SKY-0515 in Huntington's disease patients, with treated patients showing a +1.59 point difference at the primary endpoint on the unified composite scale.
Clinical Trial Data
Phase
Phase 1/2
Primary Endpoint
Met
Outcome Details
At the 15-month primary endpoint, SKY-0515-treated patients showed a +1.59 point difference in composite unified scale progression
Importance:6/10
Sentiment:
0.65
Huntington's diseaseneurologyclinical trialPhase 1/2positive data
Read the original article
Published by PR Newswire Biotech on September 17, 2026 12:07 PM